<ul>
<li>Ascendis published Week 182 results from the Phase 3 PaTHway trial of TransCon PTH in adults with hypoparathyroidism.     *      At Week 182, 96% met criteria for independence from conventional therapy; 89% had normal albumin-adjusted serum calcium.     *      Mean 24-hour urine calcium normalized by Week 26, remaining within the normal range through Week 182.     *      Renal function improved, with mean eGFR up 10.97 mL/min/1.73 m2 from baseline at Week 182.     *      Safety update showed serious TEAEs in 25% of participants; treatment-related events included injection-site reactions in 25%. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascendis Pharma A/S published the original content used to generate this news brief on June 13, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here</li>
</ul>

ASND

<p>Ascendis Pharma presented Week 182 data from the Phase 3 PaTHway trial of TransCon PTH for adult hypoparathyroidism. Results showed 96% achieved independence from conventional therapy and 89% had normal serum calcium. Renal function improved with increased eGFR, and urine calcium normalized early. Safety updates noted serious treatment-emergent adverse events in 25% of participants.</p>

Ascendis Pharma posts PaTHway trial Week 182 TransCon PTH data presentation for hypoparathyroidism adults